AVRO Avrobio
- 1.3500
- +0.1200+9.76%
- 1.3300
- -0.0200-1.48%
Avrobio News
AVROBIO's Pivot and Tectonic Merger: Navigating the New Complex Regulatory Terrain
Avrobio | 10-Q: Quarterly report
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients With Preserved Ejection Fraction Heart Failure
Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on
AVROBIO's Strategic Ambiguity: A Commitment to Analysis With Uncertain Outcomes for Shareholders
Avrobio (AVRO) Gets a Buy From Wells Fargo
Shareholder Alert: Ademi LLP Investigates Whether AVROBIO, Inc. Has Obtained a Fair Price in Its Transaction With Tectonic
MILWAUKEE, Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic.
Avrobio Buy Rating: Undervalued Merger Potential With Tectonic and Promising Fc-relaxin Asset for G2PH
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AVROBIO, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - January 30, 2024) - Rigrodsky Law, P.A. is investigating AVROBIO, Inc. ("AVROBIO") (NASDAQ GS: AVRO) regarding possible breaches of fiduciary duties and other v
Avrobio Shares Dive 17% After Tectonic Therapeutic Deal
Avrobio shares dived 17% to $1.14 after it agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets.
Express News | AVROBIO Shares Are Trading Lower After the Company Announced It Will Acquire 100% of the Outstanding Equity Interests of Tectonic Therapeutic
Express News | Trading Halt: Halt Status Updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | AVROBIO And Tectonic Therapeutic Announce Merger In All-Stock Transaction; AVROBIO To Acquire 100% Of Outstanding Equity Interests Of Tectonic
AVROBIO: Upon Completion of Merger, Combined Co Expected to Operate Under the Name Tectonic Therapeutic and Trade on Nasdaq Under Ticker Symbol TECX >AVRO
AVROBIO: Upon Completion of Merger, Combined Co Expected to Operate Under the Name Tectonic Therapeutic and Trade on Nasdaq Under Ticker Symbol TECX >AVRO
AVROBIO: Tectonic Has Raised or Entered Into Agreements for a $130.7M Private Placement With a Syndicate of New and Existing Leading Life Sciences Investors >AVRO
AVROBIO: Tectonic Has Raised or Entered Into Agreements for a $130.7M Private Placement With a Syndicate of New and Existing Leading Life Sciences Investors >AVRO
AVROBIO: Combined Co Expected to Have Approximately $165 M in Cash and Cash Equivalents at Close to Provide Cash Runway Into Mid-2027 >AVRO
AVROBIO: Combined Co Expected to Have Approximately $165 M in Cash and Cash Equivalents at Close to Provide Cash Runway Into Mid-2027 >AVRO
AVROBIO: Combined Co to Be Nasdaq-listed, Clinical-Stage Biopharmaceutical Co Focused on Advancing Tectonic's Novel GPCR-targeted Therapeutic Proteins >AVRO
AVROBIO: Combined Co to Be Nasdaq-listed, Clinical-Stage Biopharmaceutical Co Focused on Advancing Tectonic's Novel GPCR-targeted Therapeutic Proteins >AVRO
AVROBIO: Will Acquire 100% of the Outstanding Equity Interests of Tectonic >AVRO
AVROBIO: Will Acquire 100% of the Outstanding Equity Interests of Tectonic >AVRO
AVROBIO and Tectonic Therapeutic Announce Merger
AVROBIO and Tectonic Therapeutic Announce Merger
Express News | Trading Halt: Halted at 7:55:00 A.m. ET - Trading Halt: Halt News Pending
AVROBIO Price Target Cut to $2.00/Share From $5.00 by Mizuho
AVROBIO Price Target Cut to $2.00/Share From $5.00 by Mizuho
Analysis
Price Target
No Data
